Description

Osimert(Osimertinib) indicate for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

 

Pharmacology

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumor following treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, Osimert is specific for the gate-keeper T790M mutation which increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease. Furthermore, osimertinib has shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.

 

Dosage

The recommended dose of Osimert is 80 mg once a day until disease progression or unacceptable toxicity. Osimertinib can taken with or without food. If a dose of Osimertinib missed, do not make up the missed dose and take the next dose as scheduled.

 

Administration

Administration To Patients Who Have Difficulty Swallowing Solids: Disperse tablet in 60 ml (2 ounces) of non-carbonated water only. Stir until tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 ml to 240 ml (4 to 8 ounces of) water and immediately drink.

If administration via nasogastric tube require, disperse the tablet as above in 15 ml of non-carbonated water, and then use an additional 15 ml of water to transfer any residues to the syringe. The resulting 30 ml liquid administer as per the nasogastric tube instructions with appropriate water flushes (approximately 30 ml).

 

Interaction

Strong CYP3A4 Inducers: If concurrent use is unavoidable, increase Osimert dosage to 160 mg daily when Coad ministering with a strong CYP3A inducer. Resume Osimert at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer

 

Side Effects

Common side effects are Interstitial Lung Disease or Pneumonitis, QTc Interval Prolongation, Cardiomyopathy, Keratitis

 

Pregnancy & Lactation

Use in Pregnancy: There are no or limited amount of data from the use of Osimert in pregnant women. Studies in animals have shown reproductive toxicity. Based on its mechanism of action and preclinical data, Osimertinib may cause foetal harm when administered to a pregnant woman. Administration of osimertinib to pregnant rats associate with embryolethality, reduced foetal growth and neonatal death at exposures similar to what expecte in humans. Osimertinib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Use in Lactation: It is not known whether osimertinib or its metabolites excrete in human milk. Administration to rats during gestation and early lactation associate with adverse effects, including reduce growth rates and neonatal death. There is insufficient information on the excretion of osimertinib or its metabolites in animal milk. A risk to the suckling child cannot excluded. Breast-feeding should discontinue during treatment with Osimertinib.

Fertility: There are no data on the effect of Osimertinib on human fertility. Results from animal studies have shown that Osimertinib has effects on male and female reproductive organs and could impair fertility

Therapeutic Class: Cytotoxic Chemotherapy

 

Storage Conditions

Store Osimert at room temperature between 20°C to 25°C. Safely throw away medicine that is out of date or that you no longer need. Keep Osimertinib and all medicines out of the reach of children.

 

For more Oncology medicine, visit our SHOP